{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T15:49:32Z","timestamp":1790696972805,"version":"4.1.0"},"reference-count":35,"publisher":"American Society of Hematology","issue":"15","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,8,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Immune thrombocytopenia (ITP) is an acquired bleeding disorder characterized by immunoglobulin G (IgG)\u2013mediated platelet destruction. Current therapies primarily focus on reducing antiplatelet antibodies using immunosuppression or increasing platelet production with thrombopoietin mimetics. However, there are no universally safe and effective treatments for patients presenting with severe life-threatening bleeding. The IgG-degrading enzyme of Streptococcus pyogenes (IdeS), a protease with strict specificity for IgG, prevents IgG-driven immune disorders in murine models, including ITP. In clinical trials, IdeS prevented IgG-mediated kidney transplant rejection; however, the concentration of IdeS used to remove pathogenic antibodies causes profound hypogammaglobulinemia, and IdeS is immunogenic, which limits its use. Therefore, this study sought to determine whether targeting IdeS to Fc\u03b3RIIA, a low-affinity IgG receptor on the surface of platelets, neutrophils, and monocytes, would be a viable strategy to decrease the pathogenesis of antiplatelet IgG and reduce treatment-related complications of nontargeted IdeS. We generated a recombinant protein conjugate by site-specifically linking the C-terminus of a single-chain variable fragment from an Fc\u03b3RIIA antibody, clone IV.3, to the N-terminus of IdeS (scIV.3-IdeS). Platelets treated with scIV.3-IdeS had reduced binding of antiplatelet IgG from patients with ITP and decreased platelet phagocytosis in\u00a0vitro, with no decrease in normal IgG. Treatment of mice expressing human Fc\u03b3RIIA with scIV.3-IdeS reduced thrombocytopenia in a model of ITP and significantly improved the half-life of transfused platelets expressing human Fc\u03b3RIIA. Together, these data suggest that scIV.3-IdeS can selectively remove pathogenic antiplatelet IgG and may be a potential treatment for patients with ITP and severe bleeding.<\/jats:p>","DOI":"10.1182\/bloodadvances.2022007195","type":"journal-article","created":{"date-parts":[[2022,6,23]],"date-time":"2022-06-23T18:53:15Z","timestamp":1656010395000},"page":"4645-4656","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["Anchoring IgG-degrading enzymes to the surface of platelets selectively neutralizes antiplatelet antibodies"],"prefix":"10.1182","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3887-389X","authenticated-orcid":false,"suffix":"Jr","given":"Donald R.","family":"Lynch","sequence":"first","affiliation":[{"name":"1Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emily N.","family":"Stringham","sequence":"additional","affiliation":[{"name":"2Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3458-8220","authenticated-orcid":false,"given":"Boya","family":"Zhang","sequence":"additional","affiliation":[{"name":"3Department of Pharmacology,"},{"name":"5BioInterfaces Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1062-6774","authenticated-orcid":false,"given":"Ginette","family":"Balbin-Cuesta","sequence":"additional","affiliation":[{"name":"6Cellular and Molecular Biology Program, and"},{"name":"7Medical Scientist Training Program, University of Michigan, Ann Arbor, MI; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9553-9081","authenticated-orcid":false,"given":"Brian R.","family":"Curtis","sequence":"additional","affiliation":[{"name":"8Platelet & Neutrophil Immunology Laboratory, and"},{"name":"9Blood Research Institute, Versiti, Milwaukee, WI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph S.","family":"Palumbo","sequence":"additional","affiliation":[{"name":"1Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"2Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9740-7672","authenticated-orcid":false,"given":"Colin F.","family":"Greineder","sequence":"additional","affiliation":[{"name":"3Department of Pharmacology,"},{"name":"5BioInterfaces Institute,"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin E.","family":"Tourdot","sequence":"additional","affiliation":[{"name":"1Internal Medicine, University of Cincinnati College of Medicine, Cincinnati, OH;"},{"name":"2Cancer and Blood Diseases Institute, Cincinnati Children\u2019s Hospital Medical Center, Cincinnati, OH;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"2022080815241584800_B1","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1182\/asheducation-2015.1.237","article-title":"Bleeding complications in immune thrombocytopenia","volume":"2015","author":"Arnold","year":"2015","journal-title":"Hematology Am Soc Hematol Educ Program."},{"issue":"1","key":"2022080815241584800_B2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/bjh.12235","article-title":"Neonatal alloimmune thrombocytopenia: pathogenesis, diagnosis and management","volume":"161","author":"Peterson","year":"2013","journal-title":"Br J Haematol."},{"issue":"3","key":"2022080815241584800_B3","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/sj.bmt.1702490","article-title":"Bleeding risk and platelet transfusion refractoriness in patients with acute myelogenous leukemia who undergo autologous stem cell transplantation","volume":"26","author":"Toor","year":"2000","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"2022080815241584800_B4","doi-asserted-by":"crossref","first-page":"1607","DOI":"10.1093\/emboj\/21.7.1607","article-title":"IdeS, a novel streptococcal cysteine proteinase with unique specificity for immunoglobulin G","volume":"21","author":"von Pawel-Rammingen","year":"2002","journal-title":"EMBO J."},{"issue":"22","key":"2022080815241584800_B5","doi-asserted-by":"crossref","first-page":"2427","DOI":"10.1182\/blood.2019000437","article-title":"Cleavage of anti-PF4\/heparin IgG by a bacterial protease and potential benefit in heparin-induced thrombocytopenia","volume":"133","author":"Kizlik-Masson","year":"2019","journal-title":"Blood."},{"issue":"2","key":"2022080815241584800_B6","doi-asserted-by":"crossref","first-page":"e1692","DOI":"10.1371\/journal.pone.0001692","article-title":"IdeS: a bacterial proteolytic enzyme with therapeutic potential","volume":"3","author":"Johansson","year":"2008","journal-title":"PLoS One."},{"issue":"7","key":"2022080815241584800_B7","doi-asserted-by":"crossref","first-page":"e0132011","DOI":"10.1371\/journal.pone.0132011","article-title":"Complete removal of extracellular IgG antibodies in a randomized dose-escalation phase I study with the bacterial enzyme IdeS \u2013 a novel therapeutic opportunity","volume":"10","author":"Winstedt","year":"2015","journal-title":"PLoS One."},{"issue":"1","key":"2022080815241584800_B8","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1111\/1744-9987.13718","article-title":"Anti-glomerular basement membrane disease (Goodpasture disease): from pathogenesis to plasma exchange to IdeS","volume":"26","author":"Shin","year":"2022","journal-title":"Ther Apher Dial."},{"issue":"16","key":"2022080815241584800_B9","doi-asserted-by":"crossref","first-page":"6181","DOI":"10.1073\/pnas.1203954109","article-title":"Mouse model recapitulating human Fc\u03b3 receptor structural and functional diversity","volume":"109","author":"Smith","year":"2012","journal-title":"Proc Natl Acad Sci USA."},{"key":"2022080815241584800_B10","doi-asserted-by":"crossref","first-page":"S14","DOI":"10.1097\/00043426-200312001-00004","article-title":"Role of Fcgamma receptors in the pathogenesis and treatment of idiopathic thrombocytopenic purpura","volume":"25","author":"Crow","year":"2003","journal-title":"J Pediatr Hematol Oncol."},{"issue":"5","key":"2022080815241584800_B11","doi-asserted-by":"crossref","first-page":"e12551","DOI":"10.1002\/rth2.12551","article-title":"Respective roles of glycoprotein VI and Fc\u03b3RIIA in the regulation of \u03b1IIb\u03b23-mediated platelet activation to fibrinogen, thrombus buildup, and stability","volume":"5","author":"Ahmed","year":"2021","journal-title":"Res Pract Thromb Haemost."},{"issue":"5","key":"2022080815241584800_B12","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1111\/jth.15265","article-title":"Platelet Fc\u03b3RIIA in immunity and thrombosis: adaptive immunothrombosis","volume":"19","author":"Patel","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"5","key":"2022080815241584800_B13","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.4049\/jimmunol.136.5.1641","article-title":"Human monocytes and U937 cells bear two distinct Fc receptors for IgG","volume":"136","author":"Looney","year":"1986","journal-title":"J Immunol."},{"issue":"2","key":"2022080815241584800_B14","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1136\/annrheumdis-2018-213523","article-title":"Humanised effector-null Fc\u03b3RIIA antibody inhibits immune complex-mediated proinflammatory responses","volume":"78","author":"Chen","year":"2019","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"2022080815241584800_B15","article-title":"Epitope mapping of Fc gamma RIIa monoclonal antibodies","volume":"13","author":"Sardjono","year":"2008","journal-title":"Indones J Biotechnol."},{"issue":"1","key":"2022080815241584800_B16","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1021\/acs.bioconjchem.7b00592","article-title":"Site-specific modification of single-chain antibody fragments for bioconjugation and vascular immunotargeting","volume":"29","author":"Greineder","year":"2018","journal-title":"Bioconjug Chem."},{"key":"2022080815241584800_B17","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1007\/978-1-0716-1617-8_15","article-title":"Site-specific modification of single-chain affinity ligands for fluorescence labeling, radiolabeling, and bioconjugation","volume":"2355","author":"Zhang","year":"2021","journal-title":"Methods Mol Biol."},{"issue":"1-2","key":"2022080815241584800_B18","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jim.2010.12.016","article-title":"A robust, high-throughput assay to determine the phagocytic activity of clinical antibody samples","volume":"366","author":"Ackerman","year":"2011","journal-title":"J Immunol Methods."},{"issue":"1","key":"2022080815241584800_B19","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1111\/imr.12370","article-title":"The platelet Fc receptor, Fc\u03b3RIIa","volume":"268","author":"Qiao","year":"2015","journal-title":"Immunol Rev."},{"issue":"1","key":"2022080815241584800_B20","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1042\/BJ20081126","article-title":"Identification of Tspan9 as a novel platelet tetraspanin and the collagen receptor GPVI as a component of tetraspanin microdomains","volume":"417","author":"Protty","year":"2009","journal-title":"Biochem J."},{"key":"2022080815241584800_B21","first-page":"1019","article-title":"Investigation of the mechanisms of monoclonal antibody-induced platelet activation","author":"Horsewood","year":"1991"},{"issue":"12","key":"2022080815241584800_B22","doi-asserted-by":"crossref","first-page":"5638","DOI":"10.4049\/jimmunol.157.12.5638","article-title":"Differential activation of human platelets induced by Fc gamma receptor II cross-linking and by anti-CD9 monoclonal antibody","volume":"157","author":"Qi","year":"1996","journal-title":"J Immunol."},{"issue":"12","key":"2022080815241584800_B23","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.1016\/j.febslet.2013.04.039","article-title":"Rapid IgG heavy chain cleavage by the streptococcal IgG endopeptidase IdeS is mediated by IdeS monomers and is not due to enzyme dimerization","volume":"587","author":"Vindebro","year":"2013","journal-title":"FEBS Lett."},{"issue":"7","key":"2022080815241584800_B24","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1182\/blood-2008-02-142125","article-title":"Identification of FcgammaRIIa as the ITAM-bearing receptor mediating alphaIIbbeta3 outside-in integrin signaling in human platelets","volume":"112","author":"Boylan","year":"2008","journal-title":"Blood."},{"issue":"10","key":"2022080815241584800_B25","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1182\/blood-2012-07-443325","article-title":"Cooperative integrin\/ITAM signaling in platelets enhances thrombus formation in\u00a0vitro and in\u00a0vivo","volume":"121","author":"Zhi","year":"2013","journal-title":"Blood."},{"issue":"3","key":"2022080815241584800_B26","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.chest.2016.02.641","article-title":"A novel PF4-dependent platelet activation assay identifies patients likely to have heparin-induced thrombocytopenia\/thrombosis","volume":"150","author":"Padmanabhan","year":"2016","journal-title":"Chest."},{"key":"2022080815241584800_B27","doi-asserted-by":"crossref","first-page":"880","DOI":"10.3389\/fimmu.2018.00880","article-title":"Emerging concepts in immune thrombocytopenia","volume":"9","author":"Swinkels","year":"2018","journal-title":"Front Immunol."},{"issue":"1","key":"2022080815241584800_B28","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1182\/bloodadvances.2019000868","article-title":"A modern reassessment of glycoprotein-specific direct platelet autoantibody testing in immune thrombocytopenia","volume":"4","author":"Al-Samkari","year":"2020","journal-title":"Blood Adv."},{"issue":"3","key":"2022080815241584800_B29","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1080\/09537104.2020.1727871","article-title":"Novel scientific approaches and future research directions in understanding ITP","volume":"31","author":"Hicks","year":"2020","journal-title":"Platelets."},{"issue":"9","key":"2022080815241584800_B30","doi-asserted-by":"crossref","first-page":"2363","DOI":"10.1111\/jth.15433","article-title":"Suggested treatment of serious complications to COVID-19 vaccination with IdeS, a bacterial antibody-cleaving enzyme","volume":"19","author":"Kahn","year":"2021","journal-title":"J Thromb Haemost."},{"issue":"1","key":"2022080815241584800_B31","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/bjh.15706","article-title":"Administration of immunoglobulin G-degrading enzyme of\u00a0Streptococcus pyogenes\u00a0(IdeS) for persistent anti-ADAMTS13 antibodies in patients with thrombotic thrombocytopenic purpura in clinical remission","volume":"186","author":"Stubbs","year":"2019","journal-title":"Br J Haematol."},{"issue":"7","key":"2022080815241584800_B32","doi-asserted-by":"crossref","first-page":"E1550","DOI":"10.1073\/pnas.1720553115","article-title":"Platelets release pathogenic serotonin and return to circulation after immune complex-mediated sequestration","volume":"115","author":"Cloutier","year":"2018","journal-title":"Proc Natl Acad Sci USA."},{"issue":"581","key":"2022080815241584800_B33","doi-asserted-by":"crossref","first-page":"eaav5928","DOI":"10.1126\/scitranslmed.aav5928","article-title":"Platelets release mitochondrial antigens in systemic lupus erythematosus","volume":"13","author":"Melki","year":"2021","journal-title":"Sci Transl Med."},{"issue":"1","key":"2022080815241584800_B34","doi-asserted-by":"crossref","first-page":"1322","DOI":"10.1038\/s41467-019-09160-7","article-title":"Neutrophil activation and NETosis are the major drivers of thrombosis in heparin-induced thrombocytopenia","volume":"10","author":"Perdomo","year":"2019","journal-title":"Nat Commun."},{"issue":"4","key":"2022080815241584800_B35","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1056\/NEJMc2106383","article-title":"PF4 immunoassays in vaccine-induced thrombotic thrombocytopenia","volume":"385","author":"Vayne","year":"2021","journal-title":"N Engl J Med."}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/15\/4645\/1912493\/advancesadv2022007195.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/6\/15\/4645\/1912493\/advancesadv2022007195.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T05:29:56Z","timestamp":1675920596000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/6\/15\/4645\/485684\/Anchoring-IgG-degrading-enzymes-to-the-surface-of"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":35,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2022,8,9]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2022007195","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]}}}